Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Aug;44(8):3331024241274343.
doi: 10.1177/03331024241274343.

Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study

Zaza Katsarava  1   2 , Dawn C Buse  3 , Elizabeth Leroux  4 , Michel Lanteri-Minet  5   6 , Fumihiko Sakai  7 , Manjit S Matharu  8 , Aubrey Manack Adams  9 , Karen Carr  9 , Kristina M Fanning  10 , Richard B Lipton  3
Affiliations
Free article
Multicenter Study

Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study

Zaza Katsarava et al. Cephalalgia. 2024 Aug.
Free article

Abstract

Background: Few studies of migraine have evaluated migraine disability across multiple countries using the same methodology.

Methods: This cross-sectional, web-based survey was conducted in 2021-2022 in Canada, France, Germany, Japan, UK and USA. Respondents with migraine were identified based on modified International Classification of Headache Disorders, 3rd edition, criteria. Headache features (Migraine Symptom Severity Score (MSSS, range: 0-21), presence of allodynia (Allodynia Symptom Checklist, ASC-12)) and migraine burden (Patient Health Questionnaire-4 (PHQ-4), Migraine-Specific Quality of Life questionnaire version 2.1 (MSQ v2.1), Work Productivity and Activity Impairment (WPAI) questionnaire) were evaluated.

Results: Among 14,492 respondents with migraine across countries, the mean ± SD MSSS was 15.4 ± 3.2 and 48.5% (7026/14,492) of respondents had allodynia based on ASC-12. Of all respondents living with migraine, 35.5% (5146/14,492) reported moderate to severe anxiety and/or depression symptoms. Mean ± SD MSQ v2.1 Role Function-Restrictive, Role Function-Preventive and Emotional Function domain scores were 60.7 ± 22.9, 71.5 ± 23.0 and 65.1 ± 27.2, respectively. The WPAI mean ± SD percentages of respondents who missed work or worked impaired as a result of migraine were 6.8 ± 18.1% and 41.0 ± 30.1%, respectively.

Conclusions: For every country surveyed, migraine was associated with high levels of symptom severity, with allodynia and with substantial burden.

Keywords: Disability; headache; migraine.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Zaza Katsarava, MD, has been a speaker and/or consultant for, and/or received research support from Allergan, Amgen/Novartis, Eli Lilly, Merck and Teva. Dawn C. Buse, PhD, has received grant support and honoraria from AbbVie, Amgen, Biohaven, Collegium, Eli Lilly, Lundbeck, Teva and Theranica and for work on the editorial board of Current Pain and Headache Reports and is the national principal investigator in the United States for the CaMEO-I Study. Elizabeth Leroux, MD, has received speaker fees and consulting fees from Allergan, Eli Lilly and Teva Neuroscience; consulting fees from Aralez Pharmaceuticals, McKesson Canada and Medscape; speaking fees, consulting fees and reimbursement for travel from Novartis; and reimbursement for travel from IHS-GPAC. Michel Lanteri-Minet, MD, reports personal fees for advisory boards, speaker panels, or investigation studies from Allergan, Amgen, Astellas, ATI, BMS, Boehringer, Boston Scientific, CoLucid, Convergence, GlaxoSmithKline, Grunenthal, IPSEN, Lilly, Lundbeck, Medtronic, Menarini, MSD, Novartis, Orion Pharma, Pfizer, Reckitt Benckiser, Saint-Jude, Salvia BioElectronics, Sanofi-Aventis, Teva, UCB, UPSA and Zambon. Fumihiko Sakai, MD, is a consultant, speaker or scientific advisor for Amgen, Eisai, Eli Lilly, Otsuka and Teva, and the national principal investigator in Japan for the CaMEO-I Study. Manjit Matharu, MD, serves on the advisory board for Abbott, AbbVie, Eli Lilly, Lundbeck, Medtronic, Pfizer, Salvia and Teva; has received payment for the development of educational presentations from AbbVie, electroCore, Eli Lilly, Novartis and Teva; and is the national principal investigator in the United Kingdom for the CaMEO-I Study. Aubrey Manack Adams, PhD, and Karen Carr, PhD, are employees of AbbVie and may hold AbbVie stock. Kristina M. Fanning, PhD, is managing director of MIST Research, which has received research funding from AbbVie, Allay Lamp, NYC Langone Health, Juva Health and GlaxoSmithKline via grants to the National Headache Foundation. Richard B. Lipton, MD, receives research support from the Marx Foundation, the National Headache Foundation, the National Institutes of Health and the US Food and Drug Administration. He serves as a consultant or advisory board member for or has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Dr Reddy's Laboratories (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, Vector and Vedanta Research; receives royalties from Informa and Wolff's Headache, 8th edition (Oxford University Press, 2009); holds stock/options in Axon, Biohaven, CoolTech and Manistee; and is the overall principal investigator for the CaMEO-I Study.

Publication types

LinkOut - more resources